Genomic Health Study Shows Breast Cancers in Men Display Very Similar Gene Signatures to Thos...(nd a chemotherapy benefit study publishe...),Health

Date:5/29/2009

nd a chemotherapy benefit study published in the Journal of Clinical Oncology. To date, more than 7,500 physicians have ordered more than 100,000 tests, and both Medicare and private health plans covering more than 90 percent of U.S. insured lives provided reimbursement for Oncotype DX through contracts, agreements or policy decisions. Both the American Society of Clinical Oncology and the National Comprehensive Cancer Network recommend the use of Oncotype DX for patients with node-negative breast cancer that is estrogen-receptor positive and/or progesterone-receptor positive. For more information about Oncotype DX, please visit http://www.oncotypedx.com.

About Genomic Health

Genomic Health, Inc. (Nasdaq: GHDX) is a life science company focused on the development and commercialization of genomic-based clinical laboratory services for cancer that allow physicians and patients to make individualized treatment decisions. In 2004, Genomic Health launched the Oncotype DX(R) breast cancer test, which has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in early-stage breast cancer. The company was founded in 2000 and is located in Redwood City, California. For more information, please visit http://www.genomichealth.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the applicability of clinical study results to actual outcomes, the company's plans to commercialize a test for colon cancer and the proposed timing of s
'/>"/>

SOURCE Genomic Health Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Swine Flu (H1N1) Infectivity to Increase Markedly and Lethality to Remain Low According to Latest Replikin* Peptide Genomic Data
2. First Jatropha Genome Completed by Synthetic Genomics Inc. and Asiatic Centre for Genome Technology
3. Clinical Genomics Continues Progress in Developing Biomarker Portfolio for Colorectal Cancer Testing
4. Prometheus and Rosetta Genomics Announce License and Collaboration Agreement
5. Rosetta Genomics Reports First Ever In-Vivo Efficacy Data for a Systemic MicroRNA Therapeutic for Liver Cancer
6. Transgenomic and Power3 Medical Complete Agreement for Exclusive License of Neurodegenerative Biomarker Test
7. Rosetta Genomics Announces Commercial Availability of its First MicroRNA-Based Diagnostic Test; Will Host Teleconference to Discuss Launch of Future Tests
8. St. Jude Identifies Genomic Causes of a Certain Type of Leukemia Relapse
9. GEN Reports on the Trend Toward Predictive Toxicogenomics
10. Complete Genomics and the Institute for Systems Biology Announce Partnership to Conduct the First Human Genome Population Study
11. Johns Hopkins University Researchers to Clinically Assess Rosetta Genomics miRview(TM) Squamous Assay